Ibrutinib and novel BTK inhibitors in clinical development.
about
The NF-κB Pathway and Cancer Stem CellsThe roles of stem cell memory T cells in hematological malignanciesBlinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemiaBruton's tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinibTherapeutic potential of new B cell-targeted agents in the treatment of elderly and unfit patients with chronic lymphocytic leukemiaA Methyl 4-Oxo-4-phenylbut-2-enoate with in Vivo Activity against MRSA that Inhibits MenB in the Bacterial Menaquinone Biosynthesis PathwayA polymethoxyflavone from Laggera pterodonta induces apoptosis in imatinib-resistant K562R cells via activation of the intrinsic apoptosis pathwayIbrutinib: a new frontier in the treatment of chronic lymphocytic leukemia by Bruton's tyrosine kinase inhibitionSafety, pharmacokinetics, and pharmacodynamics of BMS-986142, a novel reversible BTK inhibitor, in healthy participantsInhibition of BTK protects lungs from trauma-hemorrhagic shock-induced injury in ratsIbrutinib (imbruvica): a novel targeted therapy for chronic lymphocytic leukemia.The role of tyrosine kinases in systemic lupus erythematosus and their potential as therapeutic targets.In vitro, in vivo and ex vivo characterization of ibrutinib: a potent inhibitor of the efflux function of the transporter MRP1.Breakthrough cancer medicine and its impact on novel drug development in China: report of the US Chinese Anti-Cancer Association (USCACA) and Chinese Society of Clinical Oncology (CSCO) Joint Session at the 17th CSCO Annual Meeting.Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumabNephrotoxicity of recent anti-cancer agents.Distinct pathways regulate Syk protein activation downstream of immune tyrosine activation motif (ITAM) and hemITAM receptors in platelets.Ibrutinib in Relapsed or Refractory Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia.Prolonged and tunable residence time using reversible covalent kinase inhibitors.Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer.Irreversible dual inhibitory mode: the novel Btk inhibitor PLS-123 demonstrates promising anti-tumor activity in human B-cell lymphoma.Redirection of CD4+ and CD8+ T lymphocytes via an anti-CD3 × anti-CD19 bi-specific antibody combined with cytosine arabinoside and the efficient lysis of patient-derived B-ALL cells.Establishment and characterization of a novel MYC/BCL2 "double-hit" diffuse large B cell lymphoma cell line, RCImbruvica (Ibrutinib), First-in-Class Bruton's Tyrosine Kinase Inhibitor, Receives Expanded Indications for Patients with Relapsed Chronic Lymphocytic LeukemiaIbrutinib enhances IL-17 response by modulating the function of bone marrow derived dendritic cells.Expressions of SH3BP5, LMO3, and SNAP25 in diffuse large B-cell lymphoma cells and their association with clinical featuresA rare case of the upper extremity diffuse large B-cell lymphoma mimicking soft tissue sarcoma in an elderly patient.Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemiaImbruvica (Ibrutinib): First Drug Approved for the Treatment of Patients with Waldenström's MacroglobulinemiaPhosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics.Ibrutinib for B cell malignancies.Targeting spleen tyrosine kinase-Bruton's tyrosine kinase axis for immunologically mediated glomerulonephritis.Fact or fiction--identifying the elusive multiple myeloma stem cell.Inducible tyrosine kinase inhibitors: a review of the patent literature (2010 - 2013).Selective inhibitors of nuclear export (SINE)--a novel class of anti-cancer agents.Emerging immunotherapy and strategies directly targeting B cells for the treatment of diffuse large B-cell lymphoma.Receptor tyrosine kinase-like orphan receptor 1: a novel target for cancer immunotherapy.Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma.Novel ALK inhibitors in clinical use and development.Pharmacodynamic considerations of small molecule targeted therapy for treating B-cell malignancies in the elderly.
P2860
Q26750605-C1C15CAE-81C9-49E9-A726-69C3C5B91170Q26783681-7E7E3EBA-CE8E-4D58-BDF1-ADFD20566061Q26785828-26342B04-6A8A-423E-BB9C-0B3379137E94Q26995113-E991CB32-8984-4D1E-9A7F-103D35FE52A4Q28087378-F47CAF89-1021-4F3B-9B6A-4AC8D4264877Q28396297-13F1279F-25AF-4CAE-A608-4D5D423935D5Q28649477-FF1F3EF2-55EA-450E-B1F3-A97583773900Q33566063-95AA6994-9CD9-4497-95EB-DB18A754C807Q33653945-6C0BB22B-0B78-4BC1-AC2F-4F196BEE5910Q33827989-5BCE5786-3785-4317-9A1E-EDD6A6816550Q33920352-07101F46-1F3A-40F1-B878-C4D13BFA97F0Q34597949-B3C8A4F8-7985-44AA-A9F4-2FFF19222BC3Q34914312-B49AA247-A4BF-4B43-82C2-B72BDEF330ADQ35020443-7A01339B-B8B0-4E17-8F4E-BEA40708F6FDQ35076449-FAEC14E4-21FE-4D18-BEA4-E9C63046B372Q35310741-A82D602A-E059-4E30-B923-B549D7E45D7EQ35561060-F710FE1B-DAFE-4791-842A-7B04D21CF6C6Q35687553-ABAB2CE3-54BF-499C-93A9-301ED53A2B70Q35756228-F22B117F-843F-4074-923B-303BB3F9C4DAQ35945939-6C587547-FF46-43DE-98A9-61616C325054Q36020943-A05ED977-DF6F-4B57-AF1E-9B471A6601E6Q36131489-5964E758-1E72-45F2-9099-C03A2601A3F6Q36232304-FEB21B60-15A9-4971-B733-B6825C787D74Q36333794-7B03CBD9-DE66-4770-B82C-255B30F05BD6Q36597341-E243D22E-EBA5-454D-9D01-97F123C5B50FQ36918646-14C09058-8630-4F98-9F26-E00779BCC142Q37119773-E9DBE1CC-1C58-45FE-8C80-E99518A4BCABQ37180382-37B5B134-B333-4EB5-8C13-AACD09253FC6Q37237726-254FFE67-8FF3-4F23-A3E3-2B6B26C341DCQ37350230-EA5DBC20-A71F-4059-B059-50A876341A33Q37555418-02D992BA-7B7B-4CE0-A7F8-75D8EC2D4956Q37700471-F03A7E7D-4136-439C-BB0E-3CEC5DD6A021Q38169258-820C503B-B99B-4D44-A27E-3AD97F75736DQ38225805-5A7479CF-A1C4-4385-A594-744C75510C64Q38260357-7F897A2C-9C82-41C2-83B6-948FAA0D184FQ38311896-18834930-B79A-462A-928D-7B78A7AC11A5Q38402026-7FCBD83E-5157-4BD2-9C12-1E93113866B1Q38413580-15F5F995-2C03-4A95-97D6-1BA6F1A2774CQ38427240-94611440-317B-47FB-A2C7-85A3655F5A77Q38544216-408CC099-33A8-475C-B21A-52EB57AD99F3
P2860
Ibrutinib and novel BTK inhibitors in clinical development.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Ibrutinib and novel BTK inhibitors in clinical development.
@en
type
label
Ibrutinib and novel BTK inhibitors in clinical development.
@en
prefLabel
Ibrutinib and novel BTK inhibitors in clinical development.
@en
P2093
P2860
P921
P356
P1476
Ibrutinib and novel BTK inhibitors in clinical development.
@en
P2093
Akintunde Akinleye
Delong Liu
Nikhil Mukhi
Yamei Chen
Yongping Song
P2860
P2888
P356
10.1186/1756-8722-6-59
P577
2013-08-19T00:00:00Z
P5875
P6179
1002663036